Does NINTEDANIB ESYLATE Cause Malignant neoplasm progression? 5 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 5 reports of Malignant neoplasm progression have been filed in association with NINTEDANIB ESYLATE (Ofev). This represents 4.3% of all adverse event reports for NINTEDANIB ESYLATE.
5
Reports of Malignant neoplasm progression with NINTEDANIB ESYLATE
4.3%
of all NINTEDANIB ESYLATE reports
4
Deaths
2
Hospitalizations
How Dangerous Is Malignant neoplasm progression From NINTEDANIB ESYLATE?
Of the 5 reports, 4 (80.0%) resulted in death, 2 (40.0%) required hospitalization.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for NINTEDANIB ESYLATE. However, 5 reports have been filed with the FAERS database.
What Other Side Effects Does NINTEDANIB ESYLATE Cause?
Diarrhoea (54)
Nausea (24)
Decreased appetite (20)
Fatigue (20)
Vomiting (20)
Dyspnoea (18)
Weight decreased (17)
Off label use (16)
Constipation (13)
Dizziness (13)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which NINTEDANIB ESYLATE Alternatives Have Lower Malignant neoplasm progression Risk?
NINTEDANIB ESYLATE vs NIRAPARIB
NINTEDANIB ESYLATE vs NIRMATRELVIR\RITONAVIR
NINTEDANIB ESYLATE vs NIROGACESTAT
NINTEDANIB ESYLATE vs NIROGACESTAT HYDROBROMIDE
NINTEDANIB ESYLATE vs NIRSEVIMAB